Accessibility Menu
Lisata Therapeutics logo

Lisata Therapeutics(NASDAQ) LSTA

Current Price$2.24
Market Cap$20.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1991)-100%
5 Year-89%
1 Year-13%
1 Month-36%
Lisata Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 2.242026-07-21
Lisata Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-39.62%USD 3.712026-07-14
1 month-36.36%USD 3.522026-06-18
3 month-34.5%USD 3.422026-04-22
Year to date+20.43%USD 1.862025-12-31
1 year-13.18%USD 2.582025-07-21
3 year-35.26%USD 3.462023-07-21
5 year-89.33%USD 21.002021-07-22
Since inception-100%USD 13,686,815.661991-11-19

Lisata Therapeutics Financials at a Glance

Market Cap

$20.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$170.00K

Net Income (TTM)

-$16.35M

EPS (TTM)

-$1.86

P/E Ratio

-1.20

Dividend

$0.00

Beta (Volatility)

0.67 (Low)

Price

$2.24

Volume

1,484

Open

$2.51

Previous Close

$2.24

Daily Range

$1.95 - $2.56

52-Week Range

$1.81 - $5.07

Estimated Earnings Date

Aug 6, 2026

LSTA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lisata Therapeutics

Lisata develops therapies to help treat cancer and serious diseases. Its main products aim to improve how medicines reach and affect damaged tissues. These treatments target patients with hard-to-treat tumors or chronic conditions.

Products and Services

  • Certepetide (LSTA1/CEND-1): A peptide that helps anti-cancer drugs reach solid tumors; no product sales revenue reported.
  • HONEDRA: Cell therapy in trials for critical limb ischemia, a severe blood flow problem; no product sales revenue reported.
  • XOWNA: Cell therapy in trials for coronary microvascular dysfunction, a heart condition; no product sales revenue reported.
  • CLBS201: Cell therapy for chronic kidney disease before dialysis; no product sales revenue reported.
  • Licensing and Collaboration: Revenue from agreements with partners, not from product sales; 100% of 2025 revenue.

Growth and Expansion

  • Signed a non-exclusive license with Catalent in October 2025 for certepetide use in antibody drug conjugates.
  • Regained all rights to certepetide in Greater China after ending agreement with Qilu Pharmaceutical in January 2026.
  • Entered and later ended a license with Kuva Labs for imaging technology in 2025.
  • Expanded clinical trials to new cancer types, including pancreatic and brain tumors, since 2024.
  • Operates mainly in the US, with a subsidiary in Australia supporting global research efforts.

What Makes Lisata Stand Out

Lisata’s technology helps existing cancer drugs work better by improving their delivery into tumors. The company partners with others to apply its platform in both treatment and diagnostics. Its approach focuses on combining new science with established therapies to speed up development.

Five Things You Need to Know

  • Revenue was $0.2 million in 2025, down 80% from 2024.
  • Net loss was $16.6 million in 2025, improving 17% from 2024.
  • Cash and cash equivalents were $16.0 million at December 31, 2025.
  • All 2025 revenue came from licensing and collaboration, not product sales.
  • Lisata had 21 full-time employees at the end of 2025.

Bottom Line

Lisata has shifted from early research to clinical trials, focusing on drug delivery for cancer. The company relies on partnerships and licensing to fund its ongoing development.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

21

CEO

David J. Mazzo, PhD

Website

www.lisata.com

Headquarters

Basking Ridge, NJ 07920, US

LSTA Financials

Key Financial Metrics (TTM)

Gross Margin

98.82%

Operating Margin

-10178.24%

Net Income Margin

-9618.24%

Return on Equity

-101.90%

Return on Capital

-122.58%

Return on Assets

-116.30%

Earnings Yield

-83.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$20.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

9.11M

Volume

1.48K

Avg. Volume

108.19K

Financials (TTM)

Gross Profit

$168.00K

Operating Income

-$17.30M

EBITDA

-$16.63M

Operating Cash Flow

-$13.63M

Capital Expenditure

-$28.00K

Free Cash Flow

-$13.66M

Cash & ST Invst.

$13.06M

Total Debt

$0.00

Lisata Therapeutics Performance Analysis

Lisata Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 1,000,000N/A
20252025-12-31USD 170,000-83.0%
Lisata Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30-100.0%
Q42025-12-31N/A
Q12026-03-31-100.0%
Lisata Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -10.4740.5%
20232023-12-31USD -2.58-75.3%
20242024-12-31USD -2.40-7.1%
20252025-12-31USD -1.91-20.4%
Lisata Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-301.8%
Q32025-09-309.3%
Q42025-12-3132.7%
Q12026-03-31-51.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$2.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$20.40MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$971.35K

N/A

Employees

21

N/A

Net Income

-$4.49M

+5.0%

EBITDA

-$4.87M

+13.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$13.06M

-49.4%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-1.16%

N/A

Return on Invested Capital

-1.61%

N/A

Free Cash Flow

-$3.08M

+43.2%

Operating Cash Flow

-$3.08M

+42.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KLTOKlotho Neurosciences, Inc.
$0.38-7.10%
PASGPassage Bio, Inc.
$4.91+2.08%
XCURExicure, Inc.
$1.93+2.12%
NCNANuCana plc
$1.29+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$35.14+0.24%
SKHYSK Hynix
$171.94+0.14%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.31-0.06%
NOKNokia
$10.63+0.05%

Questions About LSTA

What is the current price of Lisata Therapeutics?

Lisata Therapeutics is trading at $2.24 per share.

What is the 52-week range for Lisata Therapeutics?

Over the past 52 weeks, Lisata Therapeutics has traded between $1.81 and $5.07.

How much debt does Lisata Therapeutics have?

As of the most recent reporting period, Lisata Therapeutics reported total debt of $0.00.

How much cash does Lisata Therapeutics have on hand?

Lisata Therapeutics reported $13.06M in cash and cash equivalents in its most recent financial results.

What is Lisata Therapeutics’s dividend yield?

Lisata Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services